Collaboration takes aim at abuse-deterrent drugs and formulations

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/RobertHarris000)
(Image: Getty/RobertHarris000)

Related tags In vitro Laboratory formulation CNS

PinneyAssociates and NMS Labs will plan, conduct, and analyze in vitro laboratory testing of pharmaceutical formulations to evaluate any abuse-deterrent properties, says CMO.

As per the collaborative agreement, the companies will support pharmaceutical companies developing drugs that act on the central nervous system (CNS). The companies also intend to recommend each other for related work.

“Pharmaceutical formulations are often at risk of inappropriate manipulation – whether for intentional abuse or for ease of administration,”​ explained Judy Ashworth, MD, chief medical officer, PinneyAssociates.

Together, she told us the companies will be able to help customers which need to “push the limits”​ of novel formulation “in order to test its robustness and anticipate any untoward medical outcomes related to such manipulation.”

PinneyAssociates will lead the regulatory strategy and independent interpretation, while NMS Labs serves as the certified clinical and forensic reference laboratory, Ashworth explained.

As per the agreement, “Both companies have been operating independently in the area of abuse-deterrent formulation evaluations,”​ Ashworth said. “By teaming up, we can provide world-class strategy, implementation, and interpretation of in vitro laboratory assessments of formulations and products.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers

Follow us